Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2010

01-08-2010 | Original Article

Very low but stable glomerular filtration rate after living kidney donation: is the concept of “chronic kidney disease” applicable to kidney donors?

Authors: Ryo Kido, Yugo Shibagaki, Kazuhiro Iwadoh, Ichiro Nakajima, Shohei Fuchinoue, Toshiro Fujita, Satoshi Teraoka

Published in: Clinical and Experimental Nephrology | Issue 4/2010

Login to get access

Abstract

Background

Renal prognosis and outcome of Japanese kidney donors, who have lower preoperative glomerular filtration rate (GFR) and are generally older than their counterparts abroad, have scarcely been investigated. Here, the longitudinal changes in renal function of Japanese kidney donors were studied to clarify the prevalence and consequences of low GFR.

Methods

We reviewed charts of the living kidney donors and followed renal function by estimated GFR (eGFR, ml/min/1.73 m2) from the time of transplantation (n = 237), until 1 (n = 162) to 3 years after donation (n = 77).

Results

Median eGFR at the time of transplant was 78.7. GFR declined by approximately 40% at 1 year after donation, and as a result, most (85%) Japanese kidney donors developed chronic kidney disease (CKD) stage 3, with a median eGFR of only 48.0. The result, that the mean change in eGFR at 1–3 years after donation showed a steady increment of 0.97 ml/min/1.73 m2 per year, was distinct from the generally accepted notion that GFR declines with age. This upward change was seen irrespective of the absolute values of eGFR at or 1 year after donation, even including a subgroup with the lowest postoperative eGFR of <40.

Conclusion

Most Japanese donors developed CKD stage 3 after donation but without subsequent progression, at least for several years. Although CKD is in general regarded to confer a significant risk for progressive kidney disease, this notion might not apply to living kidney donors with low GFR but without the risk factors for progression.
Literature
1.
go back to reference Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet. 2008;372:5–6.CrossRef Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet. 2008;372:5–6.CrossRef
2.
go back to reference Johnson EM, Remucal MJ, Gillingham KJ, Dahms RA, Najarian JS, Matas AJ. Complications and risks of living donor nephrectomy. Transplantation. 1997;64:1124–8.CrossRefPubMed Johnson EM, Remucal MJ, Gillingham KJ, Dahms RA, Najarian JS, Matas AJ. Complications and risks of living donor nephrectomy. Transplantation. 1997;64:1124–8.CrossRefPubMed
3.
go back to reference Siebels M, Theodorakis J, Schmeller N, et al. Risks and complications in 160 living kidney donors who underwent nephroureterectomy. Nephrol Dial Transpl. 2003;18:2648–54.CrossRef Siebels M, Theodorakis J, Schmeller N, et al. Risks and complications in 160 living kidney donors who underwent nephroureterectomy. Nephrol Dial Transpl. 2003;18:2648–54.CrossRef
4.
go back to reference Velosa JA, Offord KP, Schroeder DR. Effect of age, sex, and glomerular filtration rate on renal function outcome of living kidney donors. Transplantation. 1995;60:1618–21.PubMed Velosa JA, Offord KP, Schroeder DR. Effect of age, sex, and glomerular filtration rate on renal function outcome of living kidney donors. Transplantation. 1995;60:1618–21.PubMed
5.
go back to reference Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet. 1992;340:807–10.CrossRefPubMed Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet. 1992;340:807–10.CrossRefPubMed
6.
go back to reference Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors live longer. Transplantation. 1997;64:976–8.CrossRefPubMed Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors live longer. Transplantation. 1997;64:976–8.CrossRefPubMed
7.
go back to reference Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459–69.CrossRefPubMed Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459–69.CrossRefPubMed
8.
go back to reference Ramcharan T, Matas AJ. Long-term (20–37 years) follow-up of living kidney donors. Am J Transpl. 2002;2:959–64.CrossRef Ramcharan T, Matas AJ. Long-term (20–37 years) follow-up of living kidney donors. Am J Transpl. 2002;2:959–64.CrossRef
9.
go back to reference Goldfarb DA, Matin SF, Braun WE, et al. Renal outcome 25 years after donor nephrectomy. J Urol. 2001;166:2043–7.CrossRefPubMed Goldfarb DA, Matin SF, Braun WE, et al. Renal outcome 25 years after donor nephrectomy. J Urol. 2001;166:2043–7.CrossRefPubMed
10.
go back to reference Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transpl. 2007;7:2333–43.CrossRef Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transpl. 2007;7:2333–43.CrossRef
11.
go back to reference Delmonico F. A report of the Amsterdam Forum on the Care of the Live Kidney Donor: data and medical guidelines. Transplantation. 2005;79(6 Suppl):S53–66.PubMed Delmonico F. A report of the Amsterdam Forum on the Care of the Live Kidney Donor: data and medical guidelines. Transplantation. 2005;79(6 Suppl):S53–66.PubMed
12.
go back to reference Rook M, Honker HS, van Son WJ, Homan van der Heide JJ, Ploeg RJ, Navis GJ. Predictive capacity of pre-donation GFR and renal reserve capacity for donor renal function after living kidney donation. Am J Transpl. 2006;6:1653–9.CrossRef Rook M, Honker HS, van Son WJ, Homan van der Heide JJ, Ploeg RJ, Navis GJ. Predictive capacity of pre-donation GFR and renal reserve capacity for donor renal function after living kidney donation. Am J Transpl. 2006;6:1653–9.CrossRef
13.
go back to reference Lee JH, Kim SC, Han DJ, et al. Risk factors for MDRD-GFR of less than 60 mL/min per 1.73 m2 in former kidney donors. Nephrology (Carlton). 2007;12:6–600.CrossRef Lee JH, Kim SC, Han DJ, et al. Risk factors for MDRD-GFR of less than 60 mL/min per 1.73 m2 in former kidney donors. Nephrology (Carlton). 2007;12:6–600.CrossRef
14.
go back to reference Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transpl. 2006;21:2577–82.CrossRef Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transpl. 2006;21:2577–82.CrossRef
15.
go back to reference Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transpl. 2008;23:2818–26.CrossRef Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transpl. 2008;23:2818–26.CrossRef
16.
go back to reference Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.CrossRefPubMed Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.CrossRefPubMed
17.
go back to reference Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed
18.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
19.
go back to reference Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–82.CrossRefPubMed Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–82.CrossRefPubMed
20.
go back to reference Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transpl. 2006;21:2133–43.CrossRef Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transpl. 2006;21:2133–43.CrossRef
21.
go back to reference Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–19.CrossRefPubMed Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–19.CrossRefPubMed
22.
go back to reference Gracida C, Espinoza R, Cedillo U, Cancino J. Kidney transplantation with living donors: nine years of follow-up of 628 living donors. Transpl Proc. 2003;35:946–7.CrossRef Gracida C, Espinoza R, Cedillo U, Cancino J. Kidney transplantation with living donors: nine years of follow-up of 628 living donors. Transpl Proc. 2003;35:946–7.CrossRef
23.
go back to reference Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation. 2001;72:444–9.CrossRefPubMed Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. Transplantation. 2001;72:444–9.CrossRefPubMed
24.
go back to reference Garg AX, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 2006;70:1801–10.CrossRefPubMed Garg AX, Muirhead N, Knoll G, et al. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 2006;70:1801–10.CrossRefPubMed
25.
go back to reference Imai E. Equation for estimating GFR from creatinine in Japan. Nippon Rinsho. 2008;66:1725–9.PubMed Imai E. Equation for estimating GFR from creatinine in Japan. Nippon Rinsho. 2008;66:1725–9.PubMed
26.
go back to reference Wan RK, Spalding E, Winch D, Brown K, Geddes CC. Reduced kidney function in living kidney donors. Kidney Int. 2007;71:1077. (author reply).CrossRefPubMed Wan RK, Spalding E, Winch D, Brown K, Geddes CC. Reduced kidney function in living kidney donors. Kidney Int. 2007;71:1077. (author reply).CrossRefPubMed
27.
go back to reference Bertolatus JA, Goddard L. Evaluation of renal function in potential living kidney donors. Transplantation. 2001;71:256–60.CrossRefPubMed Bertolatus JA, Goddard L. Evaluation of renal function in potential living kidney donors. Transplantation. 2001;71:256–60.CrossRefPubMed
28.
go back to reference Issa N, Meyer KH, Arrigain S, et al. Evaluation of creatinine-based estimates of glomerular filtration rate in a large cohort of living kidney donors. Transplantation. 2008;86:223–30.CrossRefPubMed Issa N, Meyer KH, Arrigain S, et al. Evaluation of creatinine-based estimates of glomerular filtration rate in a large cohort of living kidney donors. Transplantation. 2008;86:223–30.CrossRefPubMed
29.
go back to reference K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–266. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–266.
30.
go back to reference Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed
31.
go back to reference Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–85.PubMed Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–85.PubMed
32.
go back to reference Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155–61.CrossRefPubMed Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155–61.CrossRefPubMed
33.
go back to reference Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed
34.
go back to reference Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806–14.PubMed Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806–14.PubMed
35.
go back to reference Poggio ED, Rule AD. A critical evaluation of chronic kidney disease—should isolated reduced estimated glomerular filtration rate be considered a ‘disease’? Nephrol Dial Transpl. 2009;24:698–700.CrossRef Poggio ED, Rule AD. A critical evaluation of chronic kidney disease—should isolated reduced estimated glomerular filtration rate be considered a ‘disease’? Nephrol Dial Transpl. 2009;24:698–700.CrossRef
36.
go back to reference Barri Y, Parker T 3rd, Kaplan B, Glassock R. Primum non Nocere: is chronic kidney disease staging appropriate in living kidney transplant donors? Am J Transpl. 2009;9:657–60.CrossRef Barri Y, Parker T 3rd, Kaplan B, Glassock R. Primum non Nocere: is chronic kidney disease staging appropriate in living kidney transplant donors? Am J Transpl. 2009;9:657–60.CrossRef
37.
go back to reference Garg AX, Prasad GV, Thiessen-Philbrook HR, et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation. 2008;86:399–406.CrossRefPubMed Garg AX, Prasad GV, Thiessen-Philbrook HR, et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation. 2008;86:399–406.CrossRefPubMed
38.
go back to reference Kido R, Shibagaki Y, Iwadoh K, et al. How do living kidney donors develop end-stage renal disease? Am J Transpl. 2009;9:2514–9.CrossRef Kido R, Shibagaki Y, Iwadoh K, et al. How do living kidney donors develop end-stage renal disease? Am J Transpl. 2009;9:2514–9.CrossRef
39.
go back to reference Ommen ES, Winston JA, Murphy B. Medical risks in living kidney donors: absence of proof is not proof of absence. Clin J Am Soc Nephrol. 2006;1:885–95.CrossRefPubMed Ommen ES, Winston JA, Murphy B. Medical risks in living kidney donors: absence of proof is not proof of absence. Clin J Am Soc Nephrol. 2006;1:885–95.CrossRefPubMed
40.
go back to reference Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006;145:185–96.PubMed Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006;145:185–96.PubMed
41.
go back to reference McClellan W, Warnock DG, McClure L, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol. 2006;17:1710–5.CrossRefPubMed McClellan W, Warnock DG, McClure L, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol. 2006;17:1710–5.CrossRefPubMed
42.
go back to reference Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68:914–24.CrossRefPubMed Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68:914–24.CrossRefPubMed
Metadata
Title
Very low but stable glomerular filtration rate after living kidney donation: is the concept of “chronic kidney disease” applicable to kidney donors?
Authors
Ryo Kido
Yugo Shibagaki
Kazuhiro Iwadoh
Ichiro Nakajima
Shohei Fuchinoue
Toshiro Fujita
Satoshi Teraoka
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0279-y

Other articles of this Issue 4/2010

Clinical and Experimental Nephrology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine